Chronic HBV Infection Clinical Trial
Official title:
A Phase 1a/1b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of EDP 514 in Healthy Subjects (Part 1), and Antiviral Activity in Nucleos(t)Ide Reverse Transcriptase Inhibitor (NUC)-Suppressed Patients With Chronic Hepatitis B Virus Infection (Part 2)
Part 1 is a randomized, double-blind, placebo-controlled study. It will assess the safety, tolerability, and pharmacokinetics of single and multiple orally administered doses of EDP-514 in healthy adult subjects. Part 2 is randomized, double -blind, placebo-controlled study including subjects with Hepatitis B Virus. It will assess the safety, tolerability, pharmacokinetics and antiviral activity of 28 Days of orally administered doses of EDP-514 in nucleos(t)ide reverse transcriptase inhibitor (NUC)-Suppressed Patients with Chronic Hepatitis B Virus Infection
Part 1 consists of two phases planned in healthy subjects: The first phase assesses single ascending doses for EDP-514 (active drug or placebo) in healthy subjects. A "fasted" and "fed" two-part cohort will also assess food effect. The second phase assesses multiple ascending doses (active drug or placebo) for 14 days in healthy subjects. Each cohort within each phase will enroll a total of 8 subjects who will be randomized to receive EDP-514 or placebo. The cohort assessing food effect will enroll 10 subjects randomized to receive EDP-514 or placebo. Part 2 assesses multiple ascending doses EDP-514 (active drug or placebo) for 28 days in nucleos(t)ide reverse transcriptase inhibitor (NUC)-Suppressed Patients with Chronic Hepatitis B Virus Infection. Each cohort in Part 2 will enroll a total of 8 subjects who will be randomized to receive EDP-514 or placebo. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04470388 -
A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment
|
Phase 1 | |
| Completed |
NCT05019040 -
Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of PA1010 in HBV Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT01943799 -
Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
|
Phase 2 | |
| Recruiting |
NCT05792761 -
A Study on Antiviral Treatment of Chronic Hepatitis B in Children
|
N/A | |
| Completed |
NCT05468060 -
Study of the Safety, Tolerability, Pharmacokinetic Characteristics of PA1010 in Healthy Subjects
|
Phase 1 | |
| Active, not recruiting |
NCT05734807 -
A Study to Evaluate the Antiviral Activity and Safety of HH-003 in Chronic Hepatitis B Subjects With Low-level Viremia
|
Phase 2 | |
| Completed |
NCT06029634 -
Effects of T-bet B Cells in Persistent Virus Control After Discontinuance of NAs in CHB Patients
|
||
| Recruiting |
NCT04147208 -
Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection
|
Phase 2 | |
| Completed |
NCT03909191 -
Serum HBV RNA Value on Chronic Hepatitis B Virus Infection Manage
|
||
| Completed |
NCT03664518 -
to Evaluate the Efficacy and Safety of Eltrombopag for Immune Thrombocytopenia With Chronic HBV Infection
|
Phase 2 | |
| Completed |
NCT05542979 -
A Study to Evaluate the Safety, Tolerability of HH-003 Injection in Participants With Chronic Hepatitis B Virus Infection
|
Phase 1 | |
| Active, not recruiting |
NCT03903796 -
Study of the Efficacy and Safety of HS-10234 in Patients With Chronic Hepatitis B Virus Infection
|
Phase 3 | |
| Completed |
NCT05851261 -
Study to Evaluate the Safety, Tolerance, Pharmacokinetics Characteristics of PA3670 Tablets in Chinese Healthy Subjects
|
Phase 1 |